BDX vs SHC
Becton Dickinson vs Sotera Health — AI-powered side-by-side comparison
BDX
Becton Dickinson
50
Watch
VS
| Metric | BDX | SHC |
|---|
| AI Score |
50
|
67
|
| Price |
$190.62
|
$19.17
|
| P/E Ratio |
57.45×
|
33.44×
|
| ROE |
6.6%
|
12.9%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
46.1%
|
54.7%
|
| Debt / Equity |
0.69×
|
3.41×
|
| Dividend Yield |
2.0%
|
0.0%
|
| RSI (14) |
77.5
|
59.0
|
| Beta |
0.258
|
1.775
|
| Expected Upside |
+2.4%
|
+1.1%
|
AI Committee View
Current Innellis committee reasoning for BDX versus SHC.
SHC leads by 17 points.
SHC scores 67/100 (Buy) versus BDX at 50/100 (Watch).
BDX Committee View
33% agreement
6 analysts
The committee is genuinely divided. Macro Analyst sees a compelling case. Value Analyst remains cautious — p/e of 53.2 is expensive by classic value standards. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- 3 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- P/E of 53.2 is expensive by classic value standards — Value
- ROE of only 3.8% -- cheap may mean cheap for a reason — Value
- Revenue declining -2.6% YoY -- this is not a growth story right now — Growth
SHC Committee View
100% agreement
4 analysts
The primary driver is 5 consecutive earnings beats -- consistent execution. The main limiting factor is sector concentration is already high (hhi 3063.01). The committee is constructive but not yet at full conviction.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- RSI at 74 is in overbought territory — Technical
- Weekly RSI at 76 -- overbought on the larger timeframe too — Technical